EXECUTIVE INTERVIEWS

• State Of The Orphan Space

  Inozyme's CEO and chairman Douglas Treco shares his thoughts about the rousing success of the Orphan Drug Act, but cautions rare disease drug developers against sky high and inaccessible drug pricing practices.

• NORD Expands Advocacy And Support For Rare Disease Patients, And Industry

  NORD's president and CEO, Peter Saltonstall, offers details on the organization's current activities and ongoing work with biopharmaceutical companies developing rare disease drugs.

• No Playbook For Leqembi: Eisai’s Long Game In Alzheimer’s Disease

  Paul Hawthorne, Eisai's EVP, purpose and chief business officer, offers insight into building a market for Leqembi, Eisai's pricing and commercial strategy, and the challenges and opportunities in Alzheimer's disease.

• Executive Outlook: Converting Innovative Science Into Predictable Returns

  Executives at Big Pharma and small biotech will be rewarded in 2024 if they can find new ways to develop and commercialize drugs in the context of an unforgiving investment, payer, and regulatory landscape.

• Manufacturing And Supply Chain: Making Space Between A Rock And A Hard Place

  Biopharmaceutical companies can’t afford to halt production lines due to manufacturing violations next year. Manufacturing and supply chain processes will require fresh thinking and flexibility in 2024.

• An Outsourcing Future Of Information Sharing And Commercial Streamlining

  Outsourced Pharma Chief Editor Louis Garguilo writes about what outsourcing professionals think about the future of working with CDMOs.

• Defining A Competitive Next-Gen RNA Therapeutic In 2024

  To start singling-out where the opportunities exist to craft the next generation of RNA therapeutics, Anna Rose Welch sat down with four RNA executives.

• Accelerating Drug Development With Real World Data

  Think real-world data’s only application is clinical trials? Think again. Savvy early-stage biotechs are leveraging RWD in their formative stages, long before entering the clinic, to drive critical efficiencies in drug discovery and development.

• Finance And Funding: Anticipating Improvement, Planning For Uncertainty

  Executives responding to this year’s finance and funding outlook questions are optimistic about the potential for a turnaround in 2024.

• Biopharma’s Eminent Challenges In 2024 — Inside & Out

  A baker’s dozen of biopharma CEOs answer a call to prioritize and describe challenges they expect to face in the coming year.

• Moving Beyond AAV: The Next Generation Of Vectors In CGT

  We catch up with Dr. Konstantin Konstantinov, CTO at Ring Therapeutics, and Ryan Crisman, Ph.D., cofounder and CTO at Umoja Biopharma, to get their thoughts on the future of new anellovirus vectors and existing lentiviral vector technology for in vivo gene delivery respectively.

• Top 2024 Clinical Trial Site Challenges: Staffing & Technology

  Industry experts talk about some of the new challenges facing clinical trial sites in 2024.

• Building A Business Model For Novel Antibiotics

  In the challenging development space for novel antibiotics, Spero Therapeutics is using partnership, external validation, and formulation science to develop drugs treating bacterial infections both rare and common.

• The Power Couple Behind Krystal Biotech

  Krish and Krishnan, the husband-and-wife team that founded and leads Krystal Biotech, cleared a path to market for the first ever topical and redosable gene therapy.